D-GL conjugate therapy

Details D-GL conjugate therapy D-GL conjugate therapy

1988-10-07

1990-08-21

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Lymphokine

424 852, 424 858, 424 2, 424 9, 430 18, 430 21, 525 541, A61K 3900, A61K 3766, A61K 4300

Patent

active

049504690

ABSTRACT:
Receptor blocking technology using proteins conjugated to polymers of D-glutamic acid and D-lysine for treatment of antibody-mediated autoimmune disease, membrane and tumor disorders is disclosed.

REFERENCES:
patent: 4191668 (1980-03-01), Katz
patent: 4545985 (1985-10-01), Pastan et al.
patent: 4634682 (1987-01-01), Erickson et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 4867962 (1989-09-01), Abrams
Katz, "Hapten-Specific Tolerance Induced by the DNP Derivative of D-Glutamic Acid and D-Lysine (D-GL) Copolymer", Immunological Tolerance, Academic Press, 1974.
Benacerraf et al, "Failure to Induce Tolerance to 2,4-Dinitrochlorobenzene Contact Sensitivity with a 2,4-Dinitrophenyl (DNP) Conjugate of a Copolymer of D-Glutamic Acid and D-Lysine, A Specific Tolerogen for DNP B Cells", The Journal of Immunology, vol. 112, No. 3, Mar. 1974, pp. 1158-1163.

Affiliated with

Also associated with

Rating

D-GL conjugate therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with D-GL conjugate therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and D-GL conjugate therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1676183